The Jewel P-WCD detects and treats life-threatening ventricular tachycardia and ventricular fibrillation, and is designed to promote compliance and fit into a patient’s daily life.
Providers:
Login to the clinical portal to access important information about the Jewel.
The Jewel P-WCD detects and treats life-threatening ventricular tachycardia and ventricular fibrillation, and is designed to promote compliance and fit into a patient’s daily life.
Providers:
Login to the clinical portal to access important information about the Jewel.
The Jewel Purpose and Overview
The Jewel continuously monitors a patient’s heart activity, detects ventricular tachycardia and ventricular fibrillation, and automatically delivers an electrical shock to restore normal heart rhythms.
You have prescribed the Jewel to your patient for a temporary period so that they are protected from specific life-threatening heart rhythms 24 hours a day, 7 days a week. The Jewel is not an implanted device. It is a device that is externally worn on the patient’s skin.

Clinical Trial Description
The Jewel IDE Study
A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest.
Objective
To demonstrate the safety and clinical effectiveness of the Jewel P-WCD.
Principal Investigators

John Hummel, MD
The Ohio State University
- Director, Electrophysiology Section
- Professor of Cardiovascular Medicine
- Over 150 Publications in Cardiac Electrophysiology

Javed Butler, MD
University of Mississippi
Patrick H. Lehan Chair in Cardiovascular Research
Chairman and Professor, Department of Medicine
Over 650 Peer-reviewed Publications
Member of Editorial Boards of Several Peer-reviewed Cardiovascular Journals

Roxana Mehran, MD
Mount Sinai
Director of Interventional Cardiovascular Research and Clinical Trials
Chief Scientific Officer, Clinical Trials Center, Cardiovascular Research Foundation
Member, Board of Trustees, Society of Cardiac Angiography and Interventions
SCIENTIFIC ADVISORS

Bob Harrington, MD
Chair of Stanford University
- Interventional Cardiologist
- Professor of Medicine and Chairman of the Department of Medicine at Stanford University
- Former Director of the Duke Clinical Research Institute (DCRI)
- Author of more than 500 Articles and Edited Five Textbooks
- Member and Chair of US FDA Cardiovascular and Renal Drugs Advisory Committee

Harlan Krumholz, MD
Director of Yale Center for Outcomes Research and Evaluation
- Cardiologist
- Professor Yale School of Medicine
- Global Thought Leader on Outcomes Based Research
- Author of more than 800 Articles and Two Books
- Board of Trustees ACC
This product is not currently available for sale in the U.S.